[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354790-105":59,"doc-detail-354790-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trxr1-inhibition-sensitizes-hepatocellular-carcinoma-to-motesanib-via-an-autophagy-ros-jnker-stress-axis","TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis","","Hepatocellular carcinoma (HCC) remains highly aggressive with poor prognosis due to limited effectiveness and resistance to existing therapies. This study evaluates combining Motesanib (MOT) with Auranofin (AF) to improve treatment outcomes. The dual-targeting strategy produces strong synergistic anticancer effects in multiple experimental models. TrxR1 inhibition is identified as critical, linked to autophagy-associated ROS accumulation, sustained ER stress, and JNK activation, resulting in DNA damage, reduced proliferation, and lower cell viability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trxr1-inhibition-sensitizes-hepatocellular-carcinoma-to-motesanib-via-an-autophagy-ros-jnker-stress-axis/354790/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trxr1-inhibition-sensitizes-hepatocellular-carcinoma-to-motesanib-via-an-autophagy-ros-jnker-stress-axis/354790.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does hepatocellular carcinoma remain difficult to treat effectively?","Question",{"text":112,"@type":113},"HCC has limited benefit from current interventions and often develops innate or acquired resistance, reducing the impact of existing single-agent therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What combination therapy strategy is explored in the study?",{"text":117,"@type":113},"The study combines Motesanib (MOT) with Auranofin (AF) to enhance therapeutic outcomes against HCC and test for synergistic anticancer activity.",{"name":119,"@type":110,"acceptedAnswer":120},"How does TrxR1 inhibition contribute to the sensitization mechanism?",{"text":121,"@type":113},"TrxR1 inhibition is linked to autophagy-related ROS accumulation; disrupting autophagy via Atg5 depletion reduces ROS accumulation and attenuates cytotoxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354790,1790269344,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Du et al. Biology Direct (2026) 21:172 Biology Direct  \n[https://doi.org/10.1186/s13062-026-00874-5](https://doi.org/10.1186/s13062-026-00874-5)  \nRESEARCH Open Access  \nTrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagyROS-JNK/ER stress axis  \nShengwei Du1,3†, Peisen Zheng2†, Wen Li3, Guorong Chen3* and Hanbin Chen3*  \nAbstract  \nHepatocellular carcinoma (HCC) remains a highly aggressive malignancy with a dismal prognosis, largely due to the limited effectiveness of current therapeutic interventions. Although Motesanib (MOT) is a clinically studied VEGFRcentered inhibitor, VEGFR-targeted strategies remain limited by innate or acquired resistance. In this study, we explored a novel pharmacological strategy combining MOT with Auranofin (AF) to enhance therapeutic outcomesin HCC. Our data demonstrate that this dual-targeting approach yields robust synergistic anticancer activity across diverse experimental models. Mechanistically, we discovered that TrxR1 inhibition is critical for this sensitization, which is closely associated with autophagy-related reactive oxygen species (ROS) accumulation. Specifically, genetic depletion of Atg5 effectively suppressed ROS accumulation and attenuated cytotoxicity, suggesting that autophagy contributes to the synergistic oxidative damage. This orchestrated stress response subsequently led to sustained endoplasmic reticulum (ER) stress and JNK pathway activation, culminating in DNA damage, impaired proliferation, and reduced cell viability. Taken together, our results identify the combination of MOT and AF as a promising and mechanistically grounded treatment regimen for advanced HCC (Graphical Abstract) .  \nKeywords Hepatocellular carcinoma, Autophagy, ROS, ER stress  \nIntroduction  \nAs one of the leading causes of cancer-related death globally, hepatocellular carcinoma (HCC) is a highly common and lethal malignancy [1]. As the primary form of liver cancer, HCC typically arises in patients with chronic liver injury or cirrhosis. Known risk factors include hepatitis Bor C virus infection, long-term alcohol intake, and nonalcoholic steatohepatitis [2]. Patients with early HCC  \n†Shengwei Du and Peisen Zheng contributed equally to this work.  \n*Correspondence: Guorong Chen[chengr1978@aliyun.com](chengr1978@aliyun.com)[ ](chengr1978@aliyun.com)Hanbin Chen[chenhanbin@wmu.edu.cn](chenhanbin@wmu.edu.cn)  \nFull list of author information is available at the end of the article  \ngenerally receive the current mainstream treatment, such as surgical removal of tumors [3], liver transplantation [4], or local ablation therapies [5]. However, as earlystage HCC often has no clear symptoms, many patients are not diagnosed until the disease has progressed, making systemic therapy the principal treatment option [6]. In recent years, targeted drugs and immune checkpoint inhibitors have demonstrated efficacy in advanced HCC, though the overall survival benefit remains modest [7]. Single-agent therapy is often limited by drug resistance, tumor heterogeneity, and toxic side effects [8], therefore, combination therapy may help improve therapeutic outcomes in patients with HCC.VEGFR signaling pathway plays an important role in tumor angiogenesis, which is necessary for tumor growth and development [9, 10]. VEGFR binds to its ligands to activate a series  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creativ","cbCaisN3y2VZMPpT","https://ap.wps.com/l/cbCaisN3y2VZMPpT","pdf",12852958,16,"English","# Abstract\n# Introduction\n## Background on HCC and current therapies\n## VEGFR signaling and resistance\n## Oxidative stress, autophagy, and ROS-mediated death pathways","[{\"question\":\"Why does hepatocellular carcinoma remain difficult to treat effectively?\",\"answer\":\"HCC has limited benefit from current interventions and often develops innate or acquired resistance, reducing the impact of existing single-agent therapies.\"},{\"question\":\"What combination therapy strategy is explored in the study?\",\"answer\":\"The study combines Motesanib (MOT) with Auranofin (AF) to enhance therapeutic outcomes against HCC and test for synergistic anticancer activity.\"},{\"question\":\"How does TrxR1 inhibition contribute to the sensitization mechanism?\",\"answer\":\"TrxR1 inhibition is linked to autophagy-related ROS accumulation; disrupting autophagy via Atg5 depletion reduces ROS accumulation and attenuates cytotoxicity.\"}]","TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis | PDF",1790113964,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c94b4a0f8f423a50e1cc5f8dcc4cba8f.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c6944e5c7c5b25c96c9abd15d192c22.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e805aefde07fbfdf39d8f024586d8d4.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d373188ba73dcd5c7b3c10c07c38362.webp",980,1306]